MedTrace Logo

To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks

NCT05606107 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2022-11-04

No results posted yet for this study

Summary

Glucocorticoids are effective in the treatment of rheumatoid arthritis, but long-term use of glucocorticoids has many side effects. Tofacitinib is a new small-molecule drug targeting JAK, which has been found to act quickly. The aim of this clinical trial was to investigate the efficacy and safety of tofacitinib and low-dose glucocorticoids in inducing remission in patients with rheumatoid arthritis with moderate to high disease activity.

Conditions

Interventions

DRUG

Tofacitinib

Tofacitinib combined with other csDMARDs, but no glucocorticoids.

DRUG

Glucocorticoid

Glucocorticoid

Sponsors & Collaborators

  • Jiaxing Hospital of T.C.M

    collaborator UNKNOWN

  • Jinhua Municipal Central Hospital

    collaborator OTHER

  • SAHZU.CHANGXING CAMPUS

    collaborator UNKNOWN

  • Zhuji People's hospital

    collaborator UNKNOWN

  • Shaoxing People's Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-20
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05606107 on ClinicalTrials.gov